Confirmatory Study of NeoCart in Knee Cartilage Repair
Launched by HISTOGENICS CORPORATION · Feb 9, 2010
Trial Information
Current as of June 03, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • greater than 18 years old
- • symptomatic articular cartilage lesion of the femur and/or trochlea
- Exclusion Criteria:
- • prior surgical intervention other than debridement
- • arthritis
- • clinically significant or symptomatic vascular or neurologic disorder of the lower extremities
About Histogenics Corporation
Histogenics Corporation is a pioneering biotechnology company focused on developing innovative regenerative medicine solutions to enhance healing and recovery in orthopedic and musculoskeletal conditions. With a commitment to advancing cell-based therapies, Histogenics utilizes its proprietary technologies to create products that aim to restore damaged tissue and improve patient outcomes. The company is dedicated to conducting rigorous clinical trials to validate the safety and efficacy of its therapies, positioning itself as a leader in the field of regenerative medicine. Through strategic partnerships and a robust research pipeline, Histogenics strives to transform the treatment landscape for patients suffering from debilitating injuries and conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Philadelphia, Pennsylvania, United States
Seattle, Washington, United States
New York, New York, United States
Royal Oak, Michigan, United States
Chicago, Illinois, United States
Albuquerque, New Mexico, United States
Portland, Oregon, United States
Bloomington, Minnesota, United States
Savannah, Georgia, United States
Tucson, Arizona, United States
Murray, Utah, United States
La Mesa, California, United States
Orange, California, United States
San Francisco, California, United States
Van Nuys, California, United States
Boulder, Colorado, United States
Denver, Colorado, United States
Fort Lauderdale, Florida, United States
Orlando, Florida, United States
Boise, Idaho, United States
Greenwood, Indiana, United States
New Orleans, Louisiana, United States
Portland, Maine, United States
West Roxbury, Massachusetts, United States
Bozeman, Montana, United States
Durham, North Carolina, United States
Columbus, Ohio, United States
San Antonio, Texas, United States
New Westminster, British Columbia, Canada
London, Ontario, Canada
Patients applied
Trial Officials
Andrea Belschner
Study Director
Histogenics Corporation
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials